Merck & Co., Inc. (NYSE:MRK) is one of the best undervalued wide moat stocks.
With competition rising to the company’s cancer therapy Keytruda, Merck & Co., Inc. is setting itself up for long-term growth. On January 12, 2026, the company raised its outlook for new growth drivers. Accordingly, Merck projects $70 billion in revenue from emerging businesses by the mid-2030s.
Merck & Co., Inc. expects cardiometabolic and respiratory treatments to generate $20 billion, up from a prior forecast of $15 billion. Meanwhile, infectious disease drugs are projected at $15 billion, compared with $5 billion previously. The increase in expectations reflects accelerated launch plans and an expanding late-stage pipeline that has nearly tripled since 2021, including acquisitions like Acceleron.
The accelerated momentum was showcased earlier on January 8, 2026, when Reuters reported that Merck & Co., Inc. is working toward a $28-32 billion acquisition of Revolution Medicines, a deal not yet finalized. The deal, which could be the largest in nearly three years, is expected to add over $10 billion in risk-adjusted global sales by 2035. With this move, the company aims to offset patent expirations and strengthen its oncology pipeline.
Merck & Co., Inc., a healthcare provider, offers pharmaceutical, vaccines, biologics, and animal health products. The company focuses on innovation, pipeline expansion, and therapies for human and animal disease management worldwide.
READ NEXT: 7 Best Rising Tech Stocks to Buy Now and 12 Best Multibagger Stocks to Buy Heading into 2026.
